Ten-Year Outcome of Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer: The Randomized Controlled CROSS Trial

Long term follow up study (n=366) found an absolute overall survival benefit of 13% for neoadjuvant chemotherapy vs surgery alone with a reduced risk of death from esophageal cancer of 40% (HR, 0.60; 95% CI, 0.46 to 0.80).

Journal of Clinical Oncology